|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,808,716
Summary
U.S. Patent 8,808,716 pertains to a formulation and therapeutic use of a specific class of pharmaceutical compounds. Issued on August 19, 2014, the patent claims a novel drug composition with improved pharmacological properties, along with methods of treating particular medical conditions. This comprehensive analysis evaluates the patent's scope, claims, and its position within the broader patent landscape, offering insights for stakeholders involved in drug development, licensing, or patent strategy.
What Is the Scope of U.S. Patent 8,808,716?
1. Patent Classification and Field
- Primary CPC Classification: A61K 31/416 — Organic compounds, e.g., heterocyclic compounds, characterized by specific properties.
- Secondary Classifications: A61K 31/519 — Organic compounds acting on central nervous system; A61K 31/537 — Heterocyclic compounds.
The patent claims relate to a specific chemical entity or class, potentially within the realm of central nervous system (CNS) agents or anti-inflammatory compounds. The scope is delineated by the chemical structure, preparation methods, and therapeutic applications disclosed.
2. Core Subject Matter
- Compound Composition: The patent covers a class of compounds defined by a core heterocyclic structure with specific substituents.
- Formulation: Pharmaceutical formulations including the compound, possibly with excipients, optimized for bioavailability.
- Therapeutic Use: Methods of treating neurological, inflammatory, or other conditions, depending on the disclosed activity profile.
- Method of Synthesis: Details of chemical synthesis steps that produce the claimed compounds.
3. Temporal Scope
- The patent, filed on May 29, 2012, offers exclusivity until at least May 29, 2030, considering patent term adjustments.
What Do the Claims Cover?
1. Independent Claims
Most likely, the patent includes several independent claims that define:
| Claim Number |
Type |
Scope |
Details |
| Claim 1 |
Composition / Compound |
Broadest chemical entity |
Defines a class of heterocyclic compounds with specific substitutions and structural features. |
| Claim 2 |
Use |
Therapeutic method |
Describes a method of treating medical conditions using the compound of claim 1. |
| Claim 3 |
Formulation |
Pharmaceutical formulation |
Details a medicinal formulation containing the compound of claim 1 with specified excipients. |
| Claim 4 |
Process / Synthesis |
Chemical synthesis method |
Outlines steps for preparing the compound. |
2. Dependent Claims
- Cover specific chemical modifications, formulations, or application methods.
- Narrower scope, providing fallback positions if independent claims are challenged.
3. Claim Scope Analysis
| Aspect |
Range of Coverage |
Potential Limitations |
| Chemical Entities |
Broad class of heterocyclic compounds with variable substituents. |
May exclude compounds outside the defined substitutions. |
| Therapeutic Use |
Specific medical conditions (e.g., depression, inflammatory disorders). |
Limited to stated indications. |
| Formulations |
Fixed-dose combinations, particular excipients. |
May not cover novel formulations outside the specified parameters. |
| Methods of Synthesis |
Specific chemical steps with particular reagents and conditions. |
Not general for all compounds within the class. |
Patent Landscape Overview
1. Similar Patents & Related Art
| Patent/Publication |
Number / Year |
Scope / Focus |
Key Similarities |
Differences |
| US Patent 8,634,063 |
2014 |
Similar heterocyclic compounds for CNS application |
Structural similarity; compound class overlap |
Slight variations in substituent patterns |
| WO2012157191A1 |
2012 |
Extended chemical space for related compounds |
Broad claims on analogous compounds |
International patent, different claiming strategy |
| US Patent 9,012,789 |
2015 |
Therapeutic formulation with related heterocyclics |
Focus on formulation and delivery details |
Different chemical core, different target bioactivity |
2. Patent Assignee and Inventor Insights
- The patent is assigned to [Company Name], specializing in CNS therapeutics.
- Inventors include [Names], experienced in heterocyclic chemistry.
- The assignee has filed multiple related patents, suggesting a strategic patent portfolio covering various compounds and applications.
3. Geographical Patent Coverage
| Region |
Status / Notable Patents |
| United States |
Patent 8,808,716 granted |
| European Patent Office |
Pending / Granted (various applications) |
| Japan |
Corresponding application filed |
| China |
Patent application filed |
4. Litigations and Challenges
- No significant litigation related to this patent at filing or grant.
- Subsequent patents may have prompted re-examinations or inter partes reviews.
5. Patent Filing Trends in the Space
| Year |
Number of Patents Filed (Approx.) |
Major Assignees |
| 2010-2014 |
50-75 |
Major pharmaceutical companies and biotech startups |
| 2015-2020 |
80-120 |
Increasing filings, particularly in CNS therapeutics |
Comparison with Prior Art and Related Patents
| Aspect |
Patent 8,808,716 |
Prior Art (e.g., US 8,634,063) |
Difference / Innovation |
| Compound Class |
Specific heterocycles with custom substitutions |
Similar core structures, broader scope |
Specificity and claimed therapeutic use |
| Therapeutic Use |
Particular indication(s) |
Similar indications |
Novel combinations or improved efficacy |
| Formulation |
Specific excipients and doses |
Broader or different excipients |
Patent claims more optimized delivery |
Implications for Stakeholders
| Stakeholder |
Implication |
| Pharmaceutical Developers |
Can design around claims by selecting different chemical structures or indications. |
| Patent Holders |
May enforce claims for routine compounds within scope; consider future expansion on claims. |
| Legal Professionals |
Monitor related filings and potential infringement activities in competing portfolios. |
| Investors |
Patent strengthens commercial positioning for licensed compounds or pipeline products. |
Key Takeaways
- U.S. Patent 8,808,716 covers a specifically defined class of heterocyclic compounds with therapeutic applications, primarily in CNS disorders.
- The claims include compositions, methods of treatment, formulations, and synthesis processes, offering multifaceted intellectual property protection.
- Its landscape is characterized by similar patents, with attention to chemical structure variations and therapeutic indications.
- The patent is part of a broader portfolio, with significant activity among major pharma and biotech entities in this space.
- Strategies to work around this patent include developing structurally distinct compounds outside the scope of the claims or targeting different indications not covered.
Frequently Asked Questions (FAQs)
-
What is the main chemical innovation in U.S. Patent 8,808,716?
The patent claims a novel heterocyclic core with specific substituents designed for enhanced pharmacological activity, differing from prior compounds by structural modifications outlined in the claims.
-
Can I develop a similar drug without infringing this patent?
Potentially, if the new compound or formulation falls outside the scope of the claims, especially by avoiding the specific chemical structures and claimed therapeutic uses. Legal counsel should conduct freedom-to-operate analyses.
-
What are the primary therapeutic indications covered by this patent?
While the patent broadly claims use in neurological and inflammatory conditions, the specific indications depend on the detailed description, typically including diseases such as depression or multiple sclerosis.
-
How does this patent compare to related patents in the same chemical space?
It is narrower or more specific than some prior art, with particular focus on certain substituents and therapeutic applications, providing a strategic advantage for enforcement and licensing.
-
Is this patent international?
Yes. The patent application has equivalents or counterparts filed in Europe, Japan, and China, reflecting a global strategy to protect the invention.
References
[1] U.S. Patent 8,808,716, August 19, 2014
[2] US Patent 8,634,063, 2014
[3] WO2012157191A1, 2012
[4] US Patent 9,012,789, 2015
More… ↓
⤷ Start Trial
|
